title: Antibody therapy for acute myeloid leukemia.
abstract: Due to the high rate of relapse in younger patients and the overall poor outcome in older patients, novel therapies are needed for the treatment of acute myeloid leukemia (AML). Monoclonal antibodies have become an important treatment modality in cancer therapy. Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was approved by the US Food and Drug Administration (FDA) for the treatment of elderly patients with relapsed AML who are not candidates for standard chemotherapy. Single-agent GO and combinations with standard chemotherapeutics have been explored extensively in this disease. Hepatotoxicity and delayed myelosuppression have been dose-limiting. Its toxicity profile is reduced with decreased doses of GO and even by administering only a single infusion. In patients with acute promyelocytic leukemia (APL), the addition of GO can produce molecular remissions and is well tolerated. Targeted immunotherapy with GO for treatment of AML has produced remissions. In order to reduce toxicity and improve efficacy, its optimal dose and schedule and pairing with other standard chemotherapeutic agents need to be defined better in large clinical trials.
authors.affiliation: Department of Medicine, Leukemia Program, Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA. deborah_mulford@urmc.rochester.edu
authors.forename: Deborah
authors.initials: D
authors.lastname: Mulford
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000276:immunology; D002986:Clinical Trials as Topic; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D017493:Leukocyte Common Antigens / Q000276:immunology; D063268:Sialic Acid Binding Ig-like Lectin 3; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; C069847:CD66 antigens; D015815:Cell Adhesion Molecules; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab; D017493:Leukocyte Common Antigens; C477390:lintuzumab